These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 33549256)

  • 1. The Association Between the Use of Cholinesterase Inhibitors and Cardiovascular Events Among Older Patients With Alzheimer Disease.
    Hsiao SH; Hwang TJ; Lin FJ; Sheu JJ; Wu CH
    Mayo Clin Proc; 2021 Feb; 96(2):350-362. PubMed ID: 33549256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction.
    Shahim B; Xu H; Haugaa K; Zetterberg H; Jurga J; Religa D; Eriksdotter M
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):128-136. PubMed ID: 38224338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
    Xu H; Garcia-Ptacek S; Jönsson L; Wimo A; Nordström P; Eriksdotter M
    Neurology; 2021 Apr; 96(17):e2220-e2230. PubMed ID: 33741639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation.
    Fisher A; Carney G; Bassett K; Chappell NL
    Value Health; 2016; 19(5):688-96. PubMed ID: 27565287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia.
    Han JY; Besser LM; Xiong C; Kukull WA; Morris JC
    Alzheimer Dis Assoc Disord; 2019; 33(2):87-94. PubMed ID: 30633043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes.
    Charbonneau C; Massoud F; Dorais M; LeLorier J
    Curr Med Res Opin; 2008 Dec; 24(12):3287-94. PubMed ID: 19032117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease.
    Herrmann N; O'Regan J; Ruthirakuhan M; Kiss A; Eryavec G; Williams E; Lanctôt KL
    J Am Med Dir Assoc; 2016 Feb; 17(2):142-7. PubMed ID: 26482056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinesterase inhibitors associated with lower rate of mortality in dementia patients with heart failure: a nationwide propensity weighting study.
    Hsieh MJ; Lee CH; Chen DY; Wu CL; Huang YT; Chang SH
    Clin Auton Res; 2023 Dec; 33(6):715-726. PubMed ID: 37935929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease.
    Daiello LA; Ott BR; Festa EK; Friedman M; Miller LA; Heindel WC
    J Clin Psychopharmacol; 2010 Jun; 30(3):245-51. PubMed ID: 20473058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study.
    Kröger E; Van Marum R; Souverein P; Carmichael PH; Egberts T
    Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):276-85. PubMed ID: 25652526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands.
    Kröger E; Berkers M; Carmichael PH; Souverein P; van Marum R; Egberts T
    Am J Geriatr Pharmacother; 2012 Dec; 10(6):373-80. PubMed ID: 23217530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinesterase inhibitors for Alzheimer disease: do they provide more than symptomatic benefits?
    Suh GH; Ryu SH; Lee DW; Han C; Ju YS; Kee BS; Lee JN; Bae JN; Choi JH; Kim DJ; Lee NJ; Lee JY; Go HJ; Yi JS; Cho SJ; Jeon YW
    Am J Geriatr Psychiatry; 2011 Mar; 19(3):266-73. PubMed ID: 20808128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study.
    Gardette V; Andrieu S; Lapeyre-Mestre M; Coley N; Cantet C; Ousset PJ; Grand A; Monstastruc JL; Vellas B
    CNS Drugs; 2010 May; 24(5):431-42. PubMed ID: 20369907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinesterase inhibitors in patients with diabetes mellitus and dementia: an open-cohort study of ~23 000 patients from the Swedish Dementia Registry.
    Secnik J; Schwertner E; Alvarsson M; Hammar N; Fastbom J; Winblad B; Garcia-Ptacek S; Religa D; Eriksdotter M
    BMJ Open Diabetes Res Care; 2020 Jan; 8(1):. PubMed ID: 31958305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease.
    Nordström P; Religa D; Wimo A; Winblad B; Eriksdotter M
    Eur Heart J; 2013 Sep; 34(33):2585-91. PubMed ID: 23735859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease.
    Amuah JE; Hogan DB; Eliasziw M; Supina A; Beck P; Downey W; Maxwell CJ
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):670-9. PubMed ID: 20583207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.
    Kennedy RE; Cutter GR; Fowler ME; Schneider LS
    JAMA Netw Open; 2018 Nov; 1(7):e184080. PubMed ID: 30646339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
    Wattmo C; Wallin ÅK
    Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial Cholinesterase Inhibitor Therapy Dose and Serious Events in Older Women and Men.
    Rochon PA; Gruneir A; Gill SS; Wu W; Zhu L; Herrmann N; Bell CM; Austin PC; Stall NM; McCarthy L; Giannakeas V; Alberga A; Seitz DP; Normand SL; Gurwitz JH; Bronskill SE
    J Am Geriatr Soc; 2018 Sep; 66(9):1692-1699. PubMed ID: 30019755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Régie de l'Assurance Maladie du Québec database.
    Lachaine J; Beauchemin C; Crochard A; Bineau S
    Can J Psychiatry; 2013 Apr; 58(4):195-200. PubMed ID: 23547642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.